Attenuated psychosis syndrome in DSM-5

Schizophrenia Research

Volumn 150, Issue 1, 2013, Pages 31-35

  Tsuang, Ming T ^a,b,c   Van Os, Jim ^d,e   Tandon, Rajiv ^f   Barch, Deanna M ^g   Bustillo, Juan ^h   Gaebel, Wolfgang ⁱ   Gur, Raquel E ^l   Heckers, Stephan ^j   Malaspina, Dolores ^k,m   Owen, Michael J ⁿ   Schultz, Susan ^o   Carpenter, William ^p  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b VA SAN DIEGO HEALTHCARE SYSTEM   (United States)

^c HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

^d MAASTRICHT UNIVERSITY MEDICAL CENTER   (Netherlands)

^e KING'S COLLEGE LONDON   (United Kingdom)

^f UNIVERSITY OF FLORIDA COLLEGE OF MEDICINE   (United States)

^g WASHINGTON UNIVERSITY   (United States)

^h UNIVERSITY OF NEW MEXICO   (United States)

ⁱ HEINRICH HEINE UNIVERSITY   (Germany)

^j UNIVERSITY OF PENNSYLVANIA   (United States)

^k VANDERBILT UNIVERSITY   (United States)

^l NEW YORK UNIVERSITY   (United States)

^m Creedmoor Psychiatric Center   (United States)

ⁿ CARDIFF UNIVERSITY   (United Kingdom)

^o UNIVERSITY OF IOWA   (United States)

^p MARYLAND PSYCHIATRIC RESEARCH CENTER   (United States)

more..

Author keywords

Attenuated psychosis syndrome; High risk; Intervention; Prodromes; Schizophrenia

Indexed keywords

OMEGA 3 FATTY ACID; PLACEBO;

ANXIETY DISORDER; ARTICLE; ATTENUATED PSYCHOSIS SYNDROME; CLINICAL FEATURE; COGNITIVE THERAPY; COMORBIDITY; CONCURRENT VALIDITY; DIAGNOSTIC ACCURACY; DIFFERENTIAL DIAGNOSIS; DISEASE ASSOCIATION; DSM-5; HIGH RISK POPULATION; HUMAN; INSTRUMENT VALIDATION; MENTAL HEALTH CARE; PREVENTIVE MEDICINE; PRIORITY JOURNAL; PSYCHOLOGIC ASSESSMENT; PSYCHOSIS; SCHIZOTYPAL PERSONALITY DISORDER; SUBSTANCE ABUSE; TREATMENT OUTCOME;

ATTENUATED PSYCHOSIS SYNDROME; HIGH RISK; INTERVENTION; PRODROMES; SCHIZOPHRENIA;

DIAGNOSTIC AND STATISTICAL MANUAL OF MENTAL DISORDERS; HUMANS; PSYCHOTIC DISORDERS; RISK FACTORS; SCHIZOPHRENIA; SCHIZOPHRENIC PSYCHOLOGY;

EID: 84884138975     PISSN: 09209964     EISSN: 15732509     Source Type: Journal    
DOI: 10.1016/j.schres.2013.05.004     Document Type: Article

References (46)

1. Addington J., Cadenhead K.S., Cannon T.D., et al. North American Prodrome Longitudinal Study: a collaborative multisite approach to prodromal schizophrenia research. Schizophr. Bull. 2007, 33:665-672.
2. Addington J., Cornblatt B.A., Cadenhead K.S., et al. At clinical high risk for psychosis: outcome for non-convertors. Am. J. Psychiatry 2011, 168:800-805.
3. Addington J., Stowkowy J., Cadenhead K.S., Cornblatt B.A., McGlashan T.H., Perkins D.O., Seidman L.J., Tsuang M.T., Walker E.F., Woods S.W., Cannon T.D. Early traumatic experiences in those at clinical high risk for psychosis. Early Interv. Psychiatry 2013, (2013 Jan 24. [Epub ahead of print]).
4. Amminger G.P., Schafer M.R., Papageorgiou K., et al. Long-chain omega-3 fatty acids for indicated prevention of psychotic disorders: a randomized, placebo-controlled trial. Arch. Gen. Psychiatry 2010, 67:146-154.
5. Boonstra N., Klaasen R., Sytema S., et al. Duration of untreated psychosis and negative symptoms-a systematic review and meta-analysis of individual patient data. Schizophr. Res. 2012, 142:12-19.
6. Cannon T.D., Cornblatt B., McGorry P. The empirical status of the ultra high-risk (prodromal) research paradigm. Schizophr. Bull. 2007, 33(3):661-664.
7. Cannon T.D., Cadenhead K., Cornblatt B., et al. Prediction of psychosis in youth at high clinical risk: a multisite longitudinal study in North America. Arch. Gen. Psychiatry 2008, 65:28-37.
8. Carpenter W.T. Anticipating DSM-V. Should psychosis risk become a diagnostic class?. Schizophr. Bull. 2009, 35:841-845.
9. Carpenter W.T., van Os J. Should attenuated psychosis syndrome be a DSM-5 diagnosis?. Am. J. Psychiatry 2011, 168:460-463.
10. Corcoran C.M., First M.B., Cornblatt B. The psychosis-risk syndrome and its proposed inclusion in the DSM-V. A risk-benefit analysis. Schizophr. Res. 2010, 120:16-22.
11. Cornblatt B.A., Auther A.M., Niendam T., Smith C.W., Zinberg J., Bearden C.E., Cannon T.D. Preliminary findings for two new measures of social and role functioning in the prodromal phase of schizophrenia. Schizophr. Bull. 2007, 33(3):688-702.
12. Drake R.J., Lewis S.W. Valuing prodromal psychosis: what do we get and what is the price?. Schizophr. Res. 2010, 120:38-41.
13. Fusar-Poli P., Howes O.D., Allen P., et al. Abnormal frontostriatal interactions in people with prodromal signs of psychosis: a multimodal imaging study. Arch. Gen. Psychiatry 2010, 67:683-691.
14. Fusar-Poli P., Stone J., Broome M., et al. Thalamic glutamate levels predicts cortical response during executive functioning in subjects at high risk for psychosis. Arch. Gen. Psychiatry 2011, 68:881-890.
15. Fusar-Poli P., Bonoldi I., Yung A.R., et al. Predicting psychosis: a meta-analysis of transition outcomes in individuals at high clinical risk. Arch. Gen. Psychiatry 2012, 69:1-10.
16. Fusar-Poli P., Deste G., Smieskova R., et al. Cognitive functioning in prodromal psychosis: a meta-analysis. Arch. Gen. Psychiatry 2012, 69:562-571.
17. Fusar-Poli P., Radua J., McGuire P., Borgwardt S. Neuroanatomical maps of psychosis onset: voxel-wise meta-analysis of antipsychotic-naive VBM studies. Schizophr. Bull. 2012, 38:1297-1307.
18. Fusar-Poli P., Bechdolf A., Taylor, et al. At risk for schizophrenic or affective psychosis? A meta-analysis of ICD/DSM diagnostic outcomes in individuals at high clinical risk. Schizophr. Bull. 2012, (Epub ahead of print).
19. Fusar-Poli P., Nelson B., Valmaggia L., Yung A.R., McGuire P.K. Comorbid depressive and anxiety disorders in 509 individuals with an at-risk mental state: impact on psychopathology and transition to psychosis. Schizophr. Bull. 2012, (Nov 22).
20. Fusar-Poli P., Borgwardt S., Bechdolf A., et al. The psychosis high risk state: a comprehensive state of the art review. Arch. Gen. Psychiatry 2013, 70:107-120.
21. Gee D.G., Cannon T.D. Prediction of conversion to psychosis: review and future directions. Rev. Bras. Psiquiatr. 2011, 33(Suppl. 2):s129-s142. (Oct).
22. Giuliano A.J., Li H., Mesholam-Gately R.I., Sorenson S.M., Woodberry K.A., Seidman L.J. Neurocognition in the psychosis risk syndrome: a quantitative and qualitative review. Curr. Pharm. Des. 2012, 18(4):399-415.
23. Howes O., Montgomery A., Asselin M., et al. Elevated striatal dopamine function linked to prodromal signs of schizophrenia. Arch. Gen. Psychiatry 2009, 66:13-20.
24. Howes O.D., Bose S.K., Turkheimer F., et al. Dopamine synthesis capacity before onset of psychosis: a prospective [18F]-DOPA PET imaging study. Am. J. Psychiatry 2011, 168:1311-1317.
25. Linscott R.J., Van Os J. An updated and conservative systematic review and meta-analysis of epidemiological evidence on psychotic experiences in children and adults: on the pathway from proneness to persistence to dimensional expression across mental disorders. Psychol. Med. 2012, (Epub online publication). 10.1017/S0033291712001626.
26. McGlashan T.H., Walsh B.C., Woods S.W. The Psychosis Risk Syndrome: Handbook for Diagnosis and Follow-up 2010, Oxford University Press.
27. McGorry P., Van Os J. Redeeming diagnosis in psychiatry: timing versus specificity. Lancet 2013, 381:343-345.
28. Mechelli A., Riecher-Rossler A., Meisenzahl E.M., et al. Neuroanatomical abnormalities that predate the onset of psychosis: a multicenter study. Arch. Gen. Psychiatry 2011, 68:489-495.
29. Miller T.J., McGlashan T.H., Rosen J.L., et al. Prospective diagnosis of the initial prodrome for schizophrenia based on the Structured Interview for Prodromal Syndromes: preliminary evidence of interrater reliability and predictive validity. Am. J. Psychiatry 2002, 159:863-865.
30. Miller T.J., McGlashan T.H., Rosen J.L., et al. Prodromal assessment with the structured interview for prodromal syndromes and the scale of prodromal symptoms: predictive validity, interrater reliability, and training to reliability. Schizophr. Bull. 2003, 29:703-715.
31. Morrison A.P., French P., Stewart S.L.K., et al. Early detection and intervention evaluation for people at risk of psychosis: multisite randomised controlled trial. BMJ 2012, 344:e2233.
32. Pantelis C., Velakoulis D., McGorry P.D., et al. Neuroanatomical abnormalities before and after onset of psychosis: a cross-sectional and longitudinal MRI comparison. Lancet 2003, 361:281-288.
33. Regier D.A., Narrow W.E., Clarke D.E., Kraemer H.C., Kuramoto S.J., Kuhl E.A., Kupfer D.J. DSM-5 field trials in the United States and Canada, Part II: test-retest reliability of selected categorical diagnoses. Am. J. Psychiatry. 2013, 170(1):59-70.
34. Simon A.E., Velthorst E., Nieman D.H., et al. Ultra high-risk state for psychosis and non-transition: a systematic review. Schizophr. Res. 2011, 132:8-17.
35. Stafford M.R., Jackson H., Mayo-Wilson E., Morrison A.P., Kendall T. Early interventions to prevent psychosis: systematic review and meta-analysis. BMJ 2013, 346:f185.
36. Tandon R., Carpenter W.T. DSM-5 status of psychotic disorders: one year pre-publication. Schizophr. Bull. 2012, 39:369-370.
37. Tandon R., Carpenter W.T. Psychotic disorders in DSM-5. Psychiatrie 2013, 10:5-9.
38. Tandon R., Maj M. Nosological status and definition of schizophrenia: some considerations for DSM-V and ICD-11. Asian J. Psychiatr. 2008, 1:22-27.
39. Tandon R., Keshavan M.S., Nasrallah H.A. Schizophrenia, "just the facts". Schizophr. Res. 2008, 100:4-20.
40. Tandon N., Shah J., Keshavan M.S., Tandon R. Attenuated psychosis and the schizophrenia prodrome: current status of risk identification and psychosis prevention. Neuropsychiatry 2012, 2:345-353.
41. van der Gaag M., et al. Cognitive behavioral therapy for subjects at ultrahigh risk for developing psychosis: a randomized controlled clinical trial. Schizophr. Bull. 2012, 38(6):1180-1188. (Nov).
42. Woods S.W., Addington J., Cadenhead K.S., Cannon T.D., Cornblatt B.A., Heinssen R., Perkins D.O., Seidman L.J., Tsuang M.T., Walker E.F., McGlashan T.H. Validity of the Prodromal Risk Syndrome for First Psychosis: Findings From the North American Prodrome Longitudinal Study. Schizophr. Bull. 2009, 35(5):894-908.
43. Woods S.W., Walsh B.C., Saksa J.R., McGlashan T.H. The case for including attenuated psychotic symptom syndrome in DSM-5 as a psychosis-risk syndrome. Schizophr. Res. 2010, 123(2-3):199-207.
44. Yung A.R., Yuen H.P., McGorry P.D., et al. Mapping the onset of psychosis: the comprehensive assessment of at-risk mental states. Aust. N. Z. J. Psychiatry 2005, 39:964-971.
45. Yung A.R., Yuen H.P., Berger G., et al. Declining transition rate in ultra high risk (prodromal) services: dilution or reduction of risk?. Schizophr. Bull. 2007, 33:673-681.
46. Yung A.R., Woods S.W., Ruhrmann S., et al. Whither the attenuated psychosis syndrome?. Schizophr. Bull. 2012, 38:1130-1134.